Suppr超能文献

肥大细胞、嗜碱性粒细胞及其介质在全身麻醉药和造影剂不良反应中的作用。

Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media.

作者信息

Genovese A, Stellato C, Marsella C V, Adt M, Marone G

机构信息

Division of Clinical Immunology and Allergy, University of Naples Federico II, School of Medicine, Italy.

出版信息

Int Arch Allergy Immunol. 1996 May;110(1):13-22. doi: 10.1159/000237305.

Abstract

General anesthetics and radiocontrast media (RCM) can cause anaphylactic or anaphylactoid reactions. These are usually underdiagnosed and underreported, but their incidence is apparently rising. Their pathogenesis is complex and not completely understood, but the release of vasoactive mediators from basophils and mast cells plays a central role. The recent development of in vitro techniques to study the release of preformed (histamine and tryptase) and de novo synthesized mediators (PGD2, LTC4, and PAF) from purified basophils and mast cells has made it possible to quantify the mediator-releasing activity of anesthetics such as muscle relaxants, general anesthetics, opioids, and benzodiazepines and RCM on human basophils and mast cells isolated from lung, skin and heart tissues. The majority of general anesthetics and RCM tested induced only the release of preformed mediators (histamine and tryptase), not of the de novo synthesized eicosanoids. There was wide variability in the response of basophils and mast cells from different donors to the same drug or RCM, presumably due to the releasability parameter. Hyperosmolality is probably not the only factor responsible for basophil and mast cell activation by RCM. The in vitro release of histamine induced by anesthetic drugs and RCM was correlated with the release of tryptase. Given the longer half-life of tryptase than histamine in plasma, measurements of plasma tryptase may become a useful diagnostic tool for identifying adverse reactions to anesthetics and RCM.

摘要

全身麻醉药和放射造影剂(RCM)可引起过敏反应或类过敏反应。这些反应通常诊断不足且报告不足,但其发生率显然在上升。其发病机制复杂,尚未完全明确,但嗜碱性粒细胞和肥大细胞释放血管活性介质起着核心作用。近年来,体外技术的发展使得研究从纯化的嗜碱性粒细胞和肥大细胞中释放预先形成的介质(组胺和类胰蛋白酶)以及新合成的介质(前列腺素D2、白三烯C4和血小板活化因子)成为可能,从而能够量化肌肉松弛剂、全身麻醉药、阿片类药物和苯二氮䓬类等麻醉药以及RCM对从肺、皮肤和心脏组织分离出的人嗜碱性粒细胞和肥大细胞的介质释放活性。大多数测试的全身麻醉药和RCM仅诱导预先形成的介质(组胺和类胰蛋白酶)释放,而非新合成的类花生酸释放。不同供体的嗜碱性粒细胞和肥大细胞对同一药物或RCM的反应存在很大差异,这可能归因于释放参数。高渗性可能不是RCM激活嗜碱性粒细胞和肥大细胞的唯一因素。麻醉药和RCM诱导的组胺体外释放与类胰蛋白酶的释放相关。鉴于类胰蛋白酶在血浆中的半衰期比组胺长,血浆类胰蛋白酶的检测可能成为识别对麻醉药和RCM不良反应的有用诊断工具。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验